Bifeprunox
Phase 3Small molecule
Bifeprunox is a small molecule that works as a Serotonin 1a (5-Ht1a) Receptor Partial Agonist; Dopamine D2 Receptor Partial Agonist.[2] It is being investigated across 6 indications, with its most advanced program in Phase 3.[1]
Bifeprunox is one of 234 small molecule programs targeting Bipolar I Disorder. It is currently in Phase 3.
6
Indications
18
Total Trials
0
Active Trials
233
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
583 competitors in Schizophrenia
#DrugCompanyPhaseTrials
1Bifeprunox
SSolvay Pharmaceuticals
Phase 3
Celexa
AbbViePreclinical
Ozempic
Novo NordiskPreclinical
Resotran
TakedaPreclinical
Zocor
OOrganon and Co
Preclinical
Depakote
AbbViePreclinical
Ibrance
PfizerPreclinical
Lunesta
Akero TherapeuticsPreclinical
Permax
VValeant Pharmaceuticals
Preclinical
Catapres
Boehringer IngelheimPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Schizophrenia9 trials
Show 6 more trials
Bipolar Depression2 trials
Psychosis1 trial
Weight Change1 trial
Bipolar Disorder1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Bifeprunox. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Serotonin 1a (5-Ht1a) Receptor Partial Agonist; Dopamine D2 Receptor Partial Agonist[2]
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- SSolvay Pharmaceuticals